Potential for Excellagen in Repair of Prenatally Diagnosed Birth Defects Using Mesenchymal Stem Cells

Cardium Therapeutics has reported on a research collaboration with researchers at Boston Children’s Hospital, to assess the medical utility of Excellagen® as a delivery scaffold to seed autologous mesenchymal fetal stem cells for ex-vivo engineering of tissue grafts for transplantation into infants to repair prenatally diagnosed birth defects.

Cardium Reports On Potential Use Of Excellagen To Repair Prenatally Diagnosed Birth Defects Using Mesenchymal Stem Cells (via PR Newswire)

Download image Logo. (PRNewsFoto/Cardium Therapeutics) SAN DIEGO, Aug. 12, 2013 /PRNewswire/ — Cardium Therapeutics (NYSE MKT: CXM) today reported on a research collaboration with researchers at Boston Children’s Hospital, to assess the medical utility…

published: August 13, 2013 in: Clinical Studies/Trials, Plastic/Reconstructive, Technology

Most read

Latest

^